Pediatric epilepsy is the most common chronic neurological disease in children, affecting 0.5-2% of children worldwide, with an overall incidence rate ranging from 0.21 to 1.87 per 1000 person-years1-4. Medical management with anti-seizure medications (ASM1) serves as initial treatment. However, 10-40% of afflicted children fail to respond to optimal pharmacological therapy.5-7 Drug-resistant epilepsy (DRE) is associated with higher rates of functional disability, morbidity, mortality, and diminished quality of life for patients and their families, independent of intellectual disabilities.
4
SEP
SEP
0